[1] |
NANCHAL R, SUBRAMANIAN R, KARVELLAS CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: Cardiovascular, endocrine, hematologic, pulmonary, and renal considerations[J]. Crit Care Med, 2020, 48( 3): e173- e191. DOI: 10.1097/CCM.0000000000004192.
|
[2] |
ZHANG H, JIA L, YAO SW, et al. Value of MELD combined with serum sodium concentration in predicting the short-term outcome of patients with HBV-related acute-on-chronic liver failure in China: A meta-analysis[J]. J Clin Hepatol, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
张辉, 贾雷, 姚士伟, 等. MELD-Na评分对我国HBV相关慢加急性肝衰竭短期预后预测价值的Meta分析[J]. 临床肝胆病杂志, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
|
[3] |
ZHU Y. Professor Wang Chengbai’s experience in treating severe jaundiced liver disease with promoting qi and promoting blood circulation drugs[J]. Chin J Integr Tradit West Med Liver Dis, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018.
朱云. 汪承柏教授重用行气活血药治疗重度黄疸肝病经验[J]. 中西医结合肝病杂志, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018.
|
[4] |
LI XH. Professor Qian Ying’s considerations and strategies on treatment of chronic severe hepatitis by blocking and reversing therapy[J]. Shanghai J Tradit Chin Med, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001.
李秀惠. 钱英教授“截断逆挽法”治疗慢性重型肝炎的思路与方法[J]. 上海中医药杂志, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001.
|
[5] |
ZHANG QY, LI XH, QIAN Y, et al. Professor QIAN Ying’s experience on the treatment of chronic severe viral hepatitis[J]. J New Chin Med, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005.
张秋云, 李秀惠, 钱英, 等. 钱英教授治疗慢性病毒性重型肝炎经验介绍[J]. 新中医, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005.
|
[6] |
CHEN NS, SUN KW. Speedy treatment of serious hepatitis[J]. J New Chin Med, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001.
谌宁生, 孙克伟. 重症肝炎从快速截断论治[J]. 新中医, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001.
|
[7] |
CHENG HB. Academic discussion on professor ZHOU Zhongying’s thoughts of“Epidemic Toxin”[J]. J Tradit Chin Med, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003.
程海波. 周仲瑛“疫毒”学术思想探析[J]. 中医杂志, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003.
|
[8] |
LYU C, MAO DW, SHI QL, et al. Experience of MAO Dewen treating hepatic failure with the theory of“Toxin-Turbid causing liver failure”[J]. Liaoning J Tradit Chin Med, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009.
吕超, 毛德文, 石清兰, 等. 毛德文“毒邪-毒浊致病”学说治疗肝衰竭经验撷菁[J]. 辽宁中医杂志, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009.
|
[9] |
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
|
[10] |
LIU P. Current status of research on the pathogenesis of liver failure[J]. Chin J Pract Intern Med, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007.
刘沛. 肝衰竭发生机制研究现状[J]. 中国实用内科杂志, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007.
|
[11] |
YE YN, GAO ZL. Three shock hypotheses that my induce liver failure[J]. Infect Dis Info, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.
叶一农, 高志良. 乙型肝炎肝衰竭发生机制中的三重打击[J]. 传染病信息, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.
|
[12] |
XU HQ, LI X, TANG SH. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041.
徐华谦, 李雪, 汤善宏. 炎症反应在慢加急性肝衰竭中的作用及治疗策略[J]. 临床肝胆病杂志, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041.
|
[13] |
DENG TT, LI L, GUAN Y, et al. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028.
邓婷婷, 李莉, 关瀛, 等. 炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展[J]. 临床肝胆病杂志, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028.
|
[14] |
LI XD, XU DP. Immunopathogenesis of acute-on-chronic hepatitis B liver failure[J]. J Prac Hepatol, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030.
李晓东, 徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展[J]. 实用肝脏病杂志, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030.
|
[15] |
GWAK GY, KOH KC, KIM HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate[J]. Clin Exp Rheumatol, 2007, 25( 6): 888- 889.
|
[16] |
WANG XJ, ZHANG XP, NING Q. Immune-mediated liver failure[J]. J Clin Hepatol, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004.
王晓晶, 张小平, 宁琴. 肝衰竭的免疫发病机制[J]. 临床肝胆病杂志, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004.
|
[17] |
LI Y, CAI YM. Analysis on composition of syndrome name[J]. China J Chin Med, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414.
李奕, 蔡永敏. 证名构成解析[J]. 中医学报, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414.
|
[18] |
HE FJ. Study on constitution of Traditional Chinese Medicine and proteomics on severe exacerbation of chronic hepatitis B[D]. Nanning: Guangxi University of Traditional Chinese Medicine, 2018.
何发娟. 慢性乙型肝炎重症化倾向期中医体质类型及蛋白质组学的调查研究[D]. 南宁: 广西中医药大学, 2018.
|
[19] |
LONG FL, CHEN XM, WANG N, et al. Study on the intervention of detoxicating and stasis-resolving granules on the prognosis of acute-on-chronic liver failure based on the expression Ratio of IL-17 on CD4+T Cells[J]. Lishizhen Med Mater Med Res, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010.
龙富立, 陈小明, 王娜, 等. 基于IL-17在CD4+T细胞表达比例观察解毒化瘀颗粒对慢加急性肝衰竭预后干预的研究[J]. 时珍国医国药, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010.
|
[20] |
WANG XF, ZHONG YQ, ZHANG RZ, et al. Effect of Wenyang Huazhuo Tuihuang decoction on hepatitis B-related acute-on-chronic liver failure[J]. J Emerg Tradit Chin Med, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010.
王秀峰, 钟云青, 张荣臻, 等. 温阳化浊退黄汤治疗乙肝相关慢加急性肝衰竭的临床研究[J]. 中国中医急症, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010.
|
[21] |
CHEN YQ, MAO DW, TANG N, et al. Efficacy of modified yinchen sini tang in acute-on-chronic liver failure[J]. Chin J Exp Med Formul, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163.
陈月桥, 毛德文, 唐农, 等. 茵陈四逆汤加减治疗慢加急性肝衰竭[J]. 中国实验方剂学杂志, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163.
|
[22] |
MAO DW, LONG FL, SHENG QS, et al. Clinical study on the treatment of endotoxemia in chronic severe hepatitis with detoxicating and stasis-resolving granules[J]. J Sichuan Tradit Chin Med, 2013, 31( 6): 78- 80.
毛德文, 龙富立, 盛庆寿, 等. 解毒化瘀颗粒治疗慢性重型肝炎内毒素血症的临床研究[J]. 四川中医, 2013, 31( 6): 78- 80.
|
[23] |
WANG MG, MAO DW, ZHANG RZ, et al. Experimental study on the regulation of Cadd45a expression in hepatocytes of acute liver failure rats by detoxicating and stasis-resolving granules[J]. Lishizhen Med Mater Med Res, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015.
王明刚, 毛德文, 张荣臻, 等. 解毒化瘀颗粒调控急性肝衰竭大鼠肝细胞Cadd45a表达的实验研究[J]. 时珍国医国药, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015.
|
[24] |
QIN YX, MA YZ, JIANG Q, et al. Protective effect of detoxicating and stasis-resolving granules against D-galactosamine/lipopolysaccharide-induced acute liver failure in rats and its mechanism of action[J]. Hunan J Tradit Chin Med, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049.
覃艳新, 马玉珍, 蒋琴, 等. 解毒化瘀颗粒对D-半乳糖胺/脂多糖诱导急性肝衰竭大鼠的保护作用及机制研究[J]. 湖南中医杂志, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049.
|
[25] |
CASTILLO-DELA CRUZ P, WANEK AG, KUMAR P, et al. Intestinal IL-17R signaling constrains IL-18-driven liver inflammation by the regulation of microbiome-derived products[J]. Cell Rep, 2019, 29( 8): 2270- 2283.e7. DOI: 10.1016/j.celrep.2019.10.042.
|
[26] |
WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
|